Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1993 May;36(3):171–176. doi: 10.1007/BF01741088

Therapeutic effects of a synthetic peptide of C-reactive protein in pre-clinical tumor models

Barbara P Barna 1,✉, Deborah A Eppstein 2, Mary Jane Thomassen 3, John J Nestor Jr 2, Teresa Ho 2, Sharon V Medendorp 4, Sharad D Deodhar 1
PMCID: PMC11038124  PMID: 8439977

Abstract

Previous studies have shown that multilamellar vesicles (MLV) or other carriers containing purified human C-reactive protein (CRP) have therapeutic activity in preclinical tumor models. Here we evaluated the therapeutic effects of MLV containing novel synthetic peptides, derived from the structure of CRP, on the extent of (a) established lung metastases of fibrosarcoma T241 in C57B1/6 mice, (b) survival of C57B1/6 mice bearing established liver metastases of colon carcinoma MCA-38, and (c) primary tumor growth of Renca renal carcinoma in Balb/c mice. In all cases, a single synthetic CRP peptide, RS-83277, demonstrated significant antitumor effects comparable to that seen with intact CRP. Two other synthetic CRP peptides, RS-83287 and RS-83147, showed no therapeutic activity and were comparable to control MLV containing only buffer. None of the peptides contained sequences homologous with that of the phagocyte stimulant, tuftsin. Activity of MLV-encapsulated RS-83277 was dose-dependent, and a comparable dose of the soluble peptide, given either alone or following injection of buffer-MLV, was ineffective. These results demonstrate immunotherapeutic potential for a novel synthetic peptide derived from CRP, and endogenous acute-phase protein.

Key words: Immunotherapy, C-reactive protein, Liposomes, Synthetic peptides, Murine tumors

Footnotes

This work was supported in part by grant CA 49950 from the National Cancer Institute, and grant 43618 from the National American Cancer Society

References

  • 1.Barna BP, Deodhar SD, Gautam S, Yen-Lieberman B, Roberts D. Macrophage activation and generation of tumoricidal activity by liposome-associated human C-reactive protein. Cancer Res. 1984;44:305. [PubMed] [Google Scholar]
  • 2.Barna BP, James K, Deodhar SD. Activation of human monocyte tumoricidal activity by C-reactive protein. Cancer Res. 1987;47:3959. [PubMed] [Google Scholar]
  • 3.Barna BP, Thomassen MJ, Wiedemann HP, Ahmad M, Deodhar SD. Modulation of human alveolar macrophage tumoricidal activity by C-reactive protein. J Biol Response Mod. 1988;7:1. [PubMed] [Google Scholar]
  • 4.Buchta R, Fridkin M, Pontet M, Romeo D. Synthetic peptides from C-reactive protein containing tufsin-related sequences. Peptides. 1987;7:961. doi: 10.1016/0196-9781(86)90121-x. [DOI] [PubMed] [Google Scholar]
  • 5.Claus D, Siegel J, Petras K, Osmand A, Gewurz H. Interactions of CRP with the first component of human complement. J Immunol. 1977;119:187. [PubMed] [Google Scholar]
  • 6.Deodhar SD. Liposomes in macrophage activation by C-reactive protein (CRP): potential for cancer therapy. In: Gregoriadis G, editor. Liposomes as drug carriers. New York: Wiley; 1988. p. 447. [Google Scholar]
  • 7.Deodhar SD, James K, Chiang T, Edinger M, Barna BP. Inhibition of lung metastases in mice bearing a malignant fibrosarcoma by treatment with liposomes containing human C-reactive protein. Cancer Res. 1982;42:5084. [PubMed] [Google Scholar]
  • 8.Deodhar S, Orangio G, Chiang T, Fazio V. Experimental model for adjuvant therapy of colorectal cancer-Inhibition of liver metastases and prolongation of survival by human C-reactive protein. Am Assoc Cancer Res. 1986;27:311. [Google Scholar]
  • 9.Eppstein DA, Van der Pas MA, Fraser-Smith EB, Felgner PL, Kurahara CG, Matthews TR, Waters RV, Venuti M, Jones G, Mehta R, Lopez-Berestein G. Liposome-encapsulated muramyl dipeptide analog enhances nonspecific host immunity. Immunotherapy. 1986;2:115. [Google Scholar]
  • 10.Fidler IJ. Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines. Science. 1980;208:1469. doi: 10.1126/science.7384789. [DOI] [PubMed] [Google Scholar]
  • 11.Fidler IJ. Targeting of immunomodulators to mononuclear phagocytes for therapy of cancer. Adv Drug Deliv Res. 1988;2:69. [Google Scholar]
  • 12.Fidler IJ, Sone S, Fogler WE, Barnes ZL. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA. 1981;78:1680. doi: 10.1073/pnas.78.3.1680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Fiedel BA, Gewurz H. Cleaved forms of C-reactive protein are associated with platelet inhibition. J Immunol. 1986;136:2551. [PubMed] [Google Scholar]
  • 14.Fridkin M, Gottlieb P. Tuftsin Thr-Lys-Pro-Arg. Anatomy of an immunologically active peptide. Mol Cell Biochem. 1981;41:73. doi: 10.1007/BF00225299. [DOI] [PubMed] [Google Scholar]
  • 15.Gautam S, Deodhar S. Generation of tumoricidal effector cells by human C-reactive protein and muramyl tripeptide: a comparative study. J Biol Response Mod. 1989;8:560. [PubMed] [Google Scholar]
  • 16.Gautam S, Barna B, Chiang T, Pettay J, Deodhar S. Use of resealed erythrocytes as a delivery system for C-reactive protein (CRP) to generate macrophage-mediated tumoricidal activity. J Biol Response Mod. 1987;6:346. [PubMed] [Google Scholar]
  • 17.Goldrosen MH, Paolini N, Jr, Holyoke ED. Description of a murine model of experimental hepatic metastases. JNCI. 1986;77:823. doi: 10.1093/jnci/77.3.823. [DOI] [PubMed] [Google Scholar]
  • 18.Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc. 1958;53:457. [Google Scholar]
  • 19.Kilpatrick JM, Volanakis JE. Opsonic properties of C-reactive protein. Stimulation by phorbol myristate acetate enables human neutrophils to phagocytize C-reactive protein coated cells. J Immunol. 1985;134:3364. [PubMed] [Google Scholar]
  • 20.Lopez-Berestein G, Fainstein V, Hopfer R, Mehta K, Sullivan MP, Keating M, Rosenblum MG, Mehta R, Luna M, Hersh EM, Reuben J, Juliano RL, Brody GP. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer, a preliminary study. J Infect Dis. 1985;151:704. doi: 10.1093/infdis/151.4.704. [DOI] [PubMed] [Google Scholar]
  • 21.Matsushima K, Larsen CG, BuBois GC, Oppenheim JJ. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med. 1989;169:1485. doi: 10.1084/jem.169.4.1485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Morley JJ, Kushner I. Serum C-reactive protein levels in disease. Ann NY Acad Sci. 1982;389:406. doi: 10.1111/j.1749-6632.1982.tb22153.x. [DOI] [PubMed] [Google Scholar]
  • 23.Mortensen RF, Duskiewicz J. Mediation of CRP dependent phagocytosis through mouse macrophage Fc-receptors. J Immunol. 1977;119:1611. [PubMed] [Google Scholar]
  • 24.Murphy GP, Hrushesky WJ. A murine renal cell carcinoma. J NCI. 1973;50:1013. doi: 10.1093/jnci/50.4.1013. [DOI] [PubMed] [Google Scholar]
  • 25.Murray JL, Kleinerman ES, Cunningham JE, Tatom JR, Andrejcio K, Lepe-Zuniga J, Lamki LM, Rosenblum MG, Frost H, Gutterman JU, Fidler IJ, Krakoff IH. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J Clin Oncol. 1989;7:1915. doi: 10.1200/JCO.1989.7.12.1915. [DOI] [PubMed] [Google Scholar]
  • 26.Pepys MB, Baltz ML. Acute phase proteins with specific reference to C-reactive protein and related proteins (pentraxins) and serum amyloid A protein. Adv Immunol. 1983;34:141. doi: 10.1016/s0065-2776(08)60379-x. [DOI] [PubMed] [Google Scholar]
  • 27.Perez-Soler R, Lopez-Berestein G, Lautersztain J, Al-Baker S, Francis K, Macias-Kiger D, Raber MN, Khokhar AR. Phase I clinical and pharmacological study of liposome-entrappedcis-bisneodecanoato-trans-R,R-1-2-diaminocyclohexane platinum (II) Cancer Res. 1990;50:4254. [PubMed] [Google Scholar]
  • 28.Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Statist Soc [A] 1972;135:185. [Google Scholar]
  • 29.Phillips NC, Tsao MS. Inhibition of experimental liver tumor growth in mice by liposomes containing a lipophilic muramyl dipeptide derivative. Cancer Res. 1989;49:936. [PubMed] [Google Scholar]
  • 30.Poste G, Bucana C, Raz A, Bugelski P, Kirsh R, Fidler IJ. Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res. 1982;42:1412. [PubMed] [Google Scholar]
  • 31.Robey FA, Ohura K, Futaki S, Fujii N, Yajima H, Goldman N, Jones KD, Wahl S. Proteolysis of human C-reactive protein produces peptides with potent immunomodulating activity. J Biol Chem. 1987;262:7053. [PubMed] [Google Scholar]
  • 32.Shephard EG, Beer SM, Anderson R, Strachan AF, Nel AE, deBeer FC. Generation of biologically active C-reactive protein peptides by a neutral protease on the membrane of phorbol myristate acetate-stimulated neutrophils. J Immunol. 1989;143:2974. [PubMed] [Google Scholar]
  • 33.Shephard EG, Anderson R, Rosen O, Myer MS, Fridkin M, Strachan AF, deBeer FC. Peptides generated from C-reactive protein by a neutrophil membrane protease: amino acid sequence and effects of peptides on neutrophil oxidative metabolism and chemotaxis. J Immunol. 1990;145:1469. [PubMed] [Google Scholar]
  • 34.Sone S, Fidler IJ. Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages. J Immunol. 1980;125:2454. [PubMed] [Google Scholar]
  • 35.Stewart J, Young J. Solid phase peptide synthesis. Rockford, Ill.: Pierce Chemical Company; 1984. [Google Scholar]
  • 36.Thomassen MJ, Meeker DP, Deodhar SD, Wiedemann HP, Barna BP (1992) Activation of human monocytes and alveolar macrophages by a synthetic peptide of C-reactive protein. J Immunother (in press) [DOI] [PubMed]
  • 37.Thombre PS, Deodhar SD. Inhibition of liver metastases in murine colon adenocarcinoma by liposomes containing human C-reactive protein or crude lymphokine. Cancer Immunol Immunother. 1984;16:145. doi: 10.1007/BF00205420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Treat J, Greenspan AR, Rahman A. Liposome encapsulated doxorubicin: preliminary results of phase I and phase II trials. In: Lopez-Berestein G, Fidler IJ, editors. Liposomes in the therapy of infectious diseases and cancer. New York: Liss; 1989. p. 353. [Google Scholar]
  • 39.Wilcoxon F. Individual comparisons by ranking methods. Biometric Bull. 1945;1:80. [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES